Product Description
Indapamide, a 'water pill,' is used to reduce the swelling and fluid retention caused by heart disease. It also is used to treat high blood pressure. It causes the kidneys to get rid of unneeded water and salt from the body into the urine. (Sourced from: https://medlineplus.gov/druginfo/meds/a684062.html)
Mechanisms of Action: Potassium Channel Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: George Medicines
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, Czech Republic, Korea, New Zealand, Nigeria, Poland, Sri Lanka, United Kingdom, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Hypertension|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2020-004891-16 | P3 |
Completed |
Hypertension |
2023-12-14 |
2025-07-09 |
Treatments |
|
| BR-FIC-CT-301 | P3 |
Completed |
Hypertension |
2024-12-02 |
12% |
2024-12-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |
| TRIDENT | P3 |
Completed |
Hypertension|Stroke |
2023-12-28 |
2025-05-06 |
Treatments|Trial Status |
|
| SAL0108A103 | P3 |
Completed |
Hypertension |
2023-11-27 |
2024-07-16 |
Primary Endpoints|Treatments |
|
| GMRx2_PCT | P3 |
Completed |
Hypertension |
2023-09-19 |
14% |
2025-06-04 |
Primary Endpoints |
| GMRx2_ACT | P3 |
Completed |
Hypertension |
2023-08-11 |
16% |
2025-06-04 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments |
| CTR20220036 | P3 |
Active, not recruiting |
Hypertension |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |